var data={"title":"Rifamycins (rifampin, rifabutin, rifapentine)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Rifamycins (rifampin, rifabutin, rifapentine)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/contributors\" class=\"contributor contributor_credentials\">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The rifamycins include <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a>, and <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. Of these, rifampin is most commonly used, either as first-line therapy (in combination with other agents) for treatment of mycobacterial disease (including tuberculosis) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/1\" class=\"abstract_t\">1</a>] or for select invasive staphylococcal infections (as part of combination therapy) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Rifamycins are moderate to potent inducers of drug metabolism, which can lead to reduced bioavailability and enhanced clearance of some coadministered medications. Such interactions may be delayed in onset but persist beyond rifamycin coadministration. Therefore, patients receiving any rifamycin should have their medication regimen analyzed carefully for drug interactions; this may be done by use of the Lexi-Interact program included within UpToDate.</p><p>Issues related to pharmacology of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>, and <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> will be reviewed here. Issues related to clinical use of rifampin and rifapentine are discussed separately. (See related topics.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">RIFAMPIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is the most commonly used rifamycin for treatment of nontuberculous mycobacterial diseases, in combination with other agents [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/1\" class=\"abstract_t\">1</a>]. It is also used for treatment of treatment of tuberculosis (active and latent infection) and for prophylaxis following exposure to <em>Neisseria meningitidis</em> or <em>Haemophilus influenzae</em> and as an adjunctive agent for treatment of select deep-seated staphylococcal infections. (See related topics.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is thought to inhibit bacterial DNA-dependent RNA polymerase, which appears to occur as a result of drug binding in the polymerase subunit deep within the <span class=\"nowrap\">DNA/RNA</span> channel, facilitating direct blocking of the elongating RNA [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Resistance to <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> arises due to missense mutations in the <em>rpoB</em> gene and occurs in a variety of bacteria including <em>Mycobacterium tuberculosis</em>, <em>Staphylococcus aureus</em> (including methicillin-resistant <em>S. aureus</em> [MRSA]), <em>Streptococcus pneumoniae</em>, and Rickettsiae [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/4-7\" class=\"abstract_t\">4-7</a>].</p><p>Phenotypic (culture-based) cross-resistance between <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and the other rifamycins (<a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> and <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a>) depends on the mutation type; it is extensive but not complete [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Molecular drug susceptibility testing is providing new insights into the potential significance of these mutations in the clinical management of tuberculosis. In select cases, it may be appropriate to perform rifabutin susceptibility testing when rifampin resistance is observed [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/10\" class=\"abstract_t\">10</a>].</p><p>The rate of spontaneous resistance of <em>M. tuberculosis</em> via single-step mutation to <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> is 1 in 10<sup>8</sup> bacilli [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/11\" class=\"abstract_t\">11</a>]. The rate of resistance in other types of bacteria (eg, <em>Escherichia coli</em>, <em>S. aureus</em>, <em>Streptococcus </em>spp, and <em>N. meningitidis</em>) is much higher [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/12\" class=\"abstract_t\">12</a>]. Since the rate of development of resistance is both high and predictable, rifampin should be used as monotherapy only for prophylaxis against <em>N. meningitidis</em> or <em>H. influenzae</em>.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Spectrum of in vitro activity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intracellular penetration of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> is high, so rifampin is useful for treatment of intracellular pathogens. Its primary use (together with other agents) is in the treatment of both latent and active <em>M. tuberculosis</em>, where it demonstrates bactericidal activity against most strains. Rifampin also has activity in vitro against nontuberculous mycobacteria, including <em>Mycobacterium kansasii</em>. Activity against <em>Mycobacterium avium</em> complex organisms is variable. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-mycobacterium-avium-complex-lung-infection-in-adults\" class=\"medical medical_review\">&quot;Treatment of Mycobacterium avium complex lung infection in adults&quot;</a>.)</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> demonstrates in vitro activity against a broad spectrum of other bacteria; however, it is generally not used (with exceptions as noted) to treat or prevent these infections. Susceptible gram-positive organisms include <em>S. aureus</em>, coagulase-negative staphylococci, <em>Streptococcus pyogenes</em>, <em>Streptococcus pneumoniae</em>, viridans streptococci, and <em>Listeria monocytogenes</em>. Rifampin also has activity against <em>Chlamydia</em> spp and diverse gram-negative pathogens, including <em>Legionella</em> spp, <em>Brucella </em>spp, <em>H. influenzae</em>, <em>Haemophilus ducreyi</em>, <em>Neisseria gonorrhoeae</em>, and <em>N. meningitidis</em>.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> undergoes rapid and complete absorption after oral administration. Absorption may be formulation dependent and is improved when the oral dose is taken on an empty stomach but may be delayed or reduced if taken with food and in patients with diabetes <span class=\"nowrap\">and/or</span> HIV infection [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/13-16\" class=\"abstract_t\">13-16</a>]. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid. It concentrates intracellularly up to five times that of extracellular concentrations, primarily in polymorphonuclear leukocytes [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/17\" class=\"abstract_t\">17</a>]. The protein binding of rifampin is approximately 80 percent.</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. Renal elimination of unchanged drug is minimal (&lt;30 percent); thus, no dose adjustments are required in patients with renal insufficiency. However, caution should be used when rifampin is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins, such as <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>. (See <a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">&quot;Isoniazid hepatotoxicity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Dosing and administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual adult dose of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> for treatment of tuberculosis is 10 <span class=\"nowrap\">mg/kg</span> (maximum 600 mg daily) given daily or either twice or three times weekly by directly observed therapy. Intravenous doses are similar to those administered orally. The usual pediatric dose range is 10 to 20 <span class=\"nowrap\">mg/kg</span> per day, (up to a maximum of 600 mg) given daily or twice weekly by directly observed therapy. Oral doses should be administered one hour before or two hours after meals. The therapeutic serum concentration for rifampin against <em>M. tuberculosis </em>is a two-hour post-dose concentration of 8 to 24 <span class=\"nowrap\">microgram/mL</span>. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p>Recommended doses of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> for adults with prosthetic valve endocarditis due to <em>S. aureus </em>are up to 300 mg every eight hours [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/18\" class=\"abstract_t\">18</a>]. This may be administered for up to six weeks, in combination with other antistaphylococcal therapy. Reports of rifampin treatment for other invasive staphylococcal infections (such as osteomyelitis, prosthetic joint infections, and meningitis) generally utilize 600 mg per day (usually in two divided doses). (See <a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">&quot;Antimicrobial therapy of prosthetic valve endocarditis&quot;</a>.)</p><p>No dose adjustments are needed for patients with renal dysfunction or undergoing dialysis. Although caution should be used in administering <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> to patients with underlying hepatic dysfunction, no formal guidelines are available to guide dosing in this population. However, it is known that metabolism may be significantly altered in patients with marked hepatic impairment.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Special populations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> has been safely administered during pregnancy. Since teratogenicity has been demonstrated in laboratory animals, it should be used only if potential benefits outweigh risks.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients should be advised that <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> typically causes an orange or red-orange discoloration of body fluids (including urine, sweat, saliva, and tears).</p><p>Adverse effects associated with the administration of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> include gastrointestinal effects (nausea, vomiting, diarrhea), central nervous system effects (headache, fever), dermatologic effects (rash, itching, flushing), and hematologic effects (thrombocytopenia, neutropenia, and acute hemolytic anemia) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/19\" class=\"abstract_t\">19</a>]. Pruritus (with or without rash) can occur but may not represent a true hypersensitivity reaction; therefore, continued use may be possible in some patients.</p><p>Hepatitis is infrequently associated with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> but is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins (such as <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>), HIV coinfection, history of liver disease, regular alcohol consumption, pregnancy, or postpartum patients. A high incidence of hepatotoxicity has been observed in patients treated with a two-month regimen of rifampin and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> for latent tuberculosis infection [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/20\" class=\"abstract_t\">20</a>]. For this reason, subsequent guidelines have advised against use of this regimen.</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> can cause a flu-like syndrome beginning one to two hours after administration and resolving six to eight hours later. Typically, this syndrome occurs more commonly with intermittent rather than daily therapy, particularly at higher doses. Most patients are able to tolerate rifampin if the interval is changed from intermittent to daily.</p><p>Reactions associated with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> that should prompt discontinuation of the drug include anaphylaxis, cutaneous vasculitis, red cell aplasia, leukopenia and agranulocytosis, thrombocytopenia, disseminated intravascular coagulation, hemolytic anemia, pulmonary infiltrates, lupoid reactions, and acute renal failure.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients must be educated about possible symptoms of hepatic toxicity, including unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, pruritus, persistent fatigue, weakness or fever lasting three or more days, abdominal discomfort (particularly right upper quadrant discomfort), or easy bruising or bleeding. Arthralgias also can occur. Patients should be directly questioned at visits for these symptoms. In addition, they should immediately report any signs or symptoms that occur between visits and (if directed) should hold further treatment if symptoms are significant. All patients with such complaints should be fully evaluated clinically, including serum testing for hepatic injury.</p><p>Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> is a potent inducer of several drug-metabolizing enzymes as well as P-glycoprotein (P-gp) multidrug efflux transporters, which can lead to undetectable concentrations and therapeutic failure of other drugs. Drug interactions result from the ability of rifampin to induce cytochrome P450 CYP3A metabolism (and to a lesser extent CYP2C) and glucuronidation, thereby accelerating drug excretion, and increase intestinal P-gp mediated drug efflux, thereby reducing gastrointestinal absorption of drugs that are P-gp substrates [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/21-24\" class=\"abstract_t\">21-24</a>]. Such interactions include (but are not limited to) oral contraceptives, glucocorticoids, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, HMG-CoA reductase inhibitors (&quot;statins&quot;), macrolide antibiotics, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>, direct oral anticoagulants (eg, <a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">dabigatran</a>), <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=levothyroxine-drug-information\" class=\"drug drug_general\">levothyroxine</a>, azole antifungal agents, oral sulfonylurea hypoglycemics, several antimalarials, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>, beta-blockers, and antiretrovirals (most notably protease inhibitors, select nonnucleoside reverse-transcriptase inhibitors [eg, <a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">etravirine</a> and <a href=\"topic.htm?path=rilpivirine-drug-information\" class=\"drug drug_general\">rilpivirine</a>) and integrase inhibitors (eg, <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a>, <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a>, and <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a>).</p><p>While the onset of effect of enzyme induction (resulting in reductions in coadministered medication[s]) can be observed within hours following oral administration of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, the full effect can require up to two weeks. After rifampin discontinuation, the effect can persist while slowly abating over two weeks [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/25-28\" class=\"abstract_t\">25-28</a>]. As a result of such interaction, substantial increase in dosage of the coadministered drug may be needed when taken either concomitant or immediately following rifampin administration. In clinical scenarios where serum concentration monitoring is available for the interacting drug (eg, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>) more frequent measurements are needed when starting or stopping rifampin.</p><p>Information regarding the interactions between <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (as a treatment for tuberculosis) and antiretrovirals is dynamic. The United States Centers for Disease Control and Prevention maintains <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf&amp;token=kkT02sVuXs5PCPEO/DtNfsYTHWeQJLx6P+LbtzL+YXW0/foO4QI0FhWYCiQQxH8wd3+zyxhx6Ui8Ydd050FVIOhl5IuDIvRpccjiYOXT5Tg=&amp;TOPIC_ID=491\" target=\"_blank\" class=\"external\">guidelines</a> for management of such interactions [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].Specific interactions of rifampin with other medications may be determined by using the drug interaction tool (Lexi-Interact) included within UpToDate. This tool can be accessed via the Drug Interactions tab located in the top right corner of the screen or via the link within the Drug Interactions section of the individual drug monographs.</p><p class=\"headingAnchor\" id=\"H1657985256\"><span class=\"h1\">RIFABUTIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> has reduced potential for drug interactions (relative to <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/30\" class=\"abstract_t\">30</a>]. Therefore, it is most commonly used for treatment of select mycobacterial infections in patients receiving concomitant medications exhibiting significant interactions with rifampin (such as select antiretroviral therapies) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/31\" class=\"abstract_t\">31</a>]. Rifabutin is approved by the US Food and Drug Administration for the prevention of disseminated <em>M. avium</em> complex (MAC) disease in patients with advanced HIV infection [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H1657985262\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> inhibits DNA-dependent RNA polymerase at the beta subunit, thus preventing chain initiation [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H1657985268\"><span class=\"h2\">Resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rifampin-resistant isolates generally have been considered resistant to all rifamycins (including <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>), although phenotypic cross-resistance is not universal [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/8,9\" class=\"abstract_t\">8,9</a>]. It has been suggested that rifabutin susceptibility testing should be done in select cases when <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> resistance is observed [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/10\" class=\"abstract_t\">10</a>].</p><p class=\"headingAnchor\" id=\"H1657985274\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following a single 300 mg oral dose, mean (&plusmn;standard deviation) peak plasma <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> concentrations of 375 (&plusmn;267) <span class=\"nowrap\">ng/mL</span> have been reported [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/32\" class=\"abstract_t\">32</a>]. Absolute bioavailability averages 20 percent; significant increases (up to fourfold) from the oral solution have been observed with administration of the capsule. High-fat meals slow the rate (but not the extent) of absorption from the capsule dosage form. Rifabutin has extensive distribution and intracellular uptake. About 85 percent of the drug is bound to plasma proteins. Approximately 53 percent and 30 percent of the oral dose is excreted in the urine (primarily as metabolites) and stool, respectively. Less than 10 percent is excreted in urine as unchanged drug. A mean terminal half-life of 45 (&plusmn;17) hours was reported in healthy volunteers.</p><p class=\"headingAnchor\" id=\"H1657985280\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In adult patients with tuberculosis, dosing of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> is 5 <span class=\"nowrap\">mg/kg</span> (max 300 mg) daily or two to three times weekly (by directly observed therapy). For treatment of other mycobacterial infections (such as <em>M. avium</em> complex) in adult patients, doses of 300 <span class=\"nowrap\">mg/day</span> are generally administered [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/32\" class=\"abstract_t\">32</a>].</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> serum concentrations can be impacted by coadministration of agents that inhibit or induce CYA-3A4. In patients with HIV infection, the United States Centers for Disease Control and Prevention (CDC) recommends that rifabutin dosing for the treatment of tuberculosis be reduced (to 150 mg daily) in the setting of concomitant administration of ritonavir-boosted protease inhibitors [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>]. Subsequent rifabutin dose increases would be necessary if the interacting drugs were discontinued. In contrast, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> coadministration may significantly reduce concentrations of rifabutin. (See <a href=\"#H1657985304\" class=\"local\">'Drug interactions'</a> below.).</p><p>Doses of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> should be reduced in patients with significant renal impairment (ie, creatinine clearance &lt;30 <span class=\"nowrap\">mL/min)</span> by 50 percent.</p><p class=\"headingAnchor\" id=\"H1657985286\"><span class=\"h2\">Special populations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limited data are available for the use of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> in children and the appropriate dose unknown. In such settings, 10 to 20 <span class=\"nowrap\">mg/kg</span> (maximum dose 300 mg) may be administered once daily or intermittently two to three times weekly (by directly observed therapy) for the treatment of mycobacterial infections.</p><p><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> should not be administered as MAC prophylaxis to patients with active tuberculosis.</p><p class=\"headingAnchor\" id=\"H1657985292\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Similar to other rifamycins, hematologic toxicity (most notably neutropenia) and hepatotoxicity have been reported in patients receiving <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. Similar to <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, the risks of hepatotoxicity would be greatest in patients with predisposing factors, including administration of concomitant hepatotoxins (such as <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>), HIV coinfection, history of liver disease, regular alcohol consumption, pregnancy, or postpartum patients.</p><p>Rifabutin-induced uveitis has also been reported [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/33\" class=\"abstract_t\">33</a>]. It is generally considered a rare, dose-related event. Concomitant administration of drugs that may increase serum concentrations of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> (notably <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> or <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>) significantly increase the risk of this reaction.</p><p>Similar to other rifamycins, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> administration may result in orange or red-orange discoloration of body fluids (including urine, sweat, saliva, and tears).</p><p class=\"headingAnchor\" id=\"H1657985298\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine monitoring of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> serum concentrations is not performed. Therapeutic concentration monitoring could assist in minimizing the risk of rifabutin-related toxicities, especially in the setting of coadministration of interacting agents (such as protease inhibitors).</p><p class=\"headingAnchor\" id=\"H1657985304\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> shares the property of uridine diphosphate gluconyltransferase (UGT) 1A1 and CYP enzyme induction with other rifamycins (predominately CYP-3A4) but is generally considered less potent. However, significant interactions with rifabutin and CYP substrates do occur. As an example, coadministration of rifabutin (300 <span class=\"nowrap\">mg/day)</span> and <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (500 mg every 12 hours) decreased the area under the curve of clarithromycin by about 50 percent [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/32\" class=\"abstract_t\">32</a>]. Trough <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> concentrations are reduced by coadministration with rifabutin by about 20 percent, although standard-dose raltegravir (400 mg twice daily) is recommended with concomitant rifabutin. In contrast, coadministration of <a href=\"topic.htm?path=elvitegravir-drug-information\" class=\"drug drug_general\">elvitegravir</a> with rifabutin is not recommended due to reductions of elvitegravir trough concentrations (67 percent) when cobicistat-boosted elvitegravir is given together with rifabutin [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Because <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> is also a substrate of CYP-3A4, its concentrations may be impacted by concomitant administration of agents inhibiting or inducing this enzyme. Protease inhibitors such as <a href=\"topic.htm?path=ritonavir-drug-information\" class=\"drug drug_general\">ritonavir</a> (a potent CYP-3A4 inhibitor) may increase rifabutin serum concentrations by up to fourfold and its major metabolite by up to 35-fold [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>]. Other protease inhibitors (<a href=\"topic.htm?path=nelfinavir-drug-information\" class=\"drug drug_general\">nelfinavir</a>, amprenavir, and <a href=\"topic.htm?path=indinavir-drug-information\" class=\"drug drug_general\">indinavir</a>) are also known to significantly increase rifabutin concentrations and often require dose reductions of rifabutin (see <a href=\"#H1657985280\" class=\"local\">'Dosing'</a> above).</p><p>Coadministration of CYP-3A4 inducers may decrease serum concentrations of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. As an example, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> (a potent CYP-3A4 inducer) decreases rifabutin serum concentrations by one-third. Therefore, the CDC recommends that <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> be used as the rifamycin of choice for patients taking efavirenz-based antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Two-way interactions are also observed with agents coadministered with <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>. As an example, <a href=\"topic.htm?path=delavirdine-drug-information\" class=\"drug drug_general\">delavirdine</a> concentrations are significantly reduced by rifabutin, and delavirdine increases the plasma concentrations of rifabutin. While rifabutin coadministered with <a href=\"topic.htm?path=etravirine-drug-information\" class=\"drug drug_general\">etravirine</a> may reduce etravirine concentrations while increasing rifabutin concentrations (35 percent and 17 percent, respectively) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/34\" class=\"abstract_t\">34</a>], the CDC does not recommend dosing modifications in such situations [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Information regarding the interactions between protease inhibitors, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> (as a treatment for tuberculosis), and antiretrovirals is dynamic. The CDC maintains <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf&amp;token=kkT02sVuXs5PCPEO/DtNfsYTHWeQJLx6P+LbtzL+YXW0/foO4QI0FhWYCiQQxH8wd3+zyxhx6Ui8Ydd050FVIOhl5IuDIvRpccjiYOXT5Tg=&amp;TOPIC_ID=491\" target=\"_blank\" class=\"external\">guidelines</a> as to the management of such interactions [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Specific interactions of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> with other medications may be determined by using the drug interaction tool (Lexi-Interact) included within UpToDate. This tool can be accessed via the Drug Interactions tab located in the top right corner of the screen or via the link within the Drug Interactions section of the individual drug monographs.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">RIFAPENTINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a> has a longer half-life than <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. It has been shown to be safe but not significantly more active than a standard rifampin regimen [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/35\" class=\"abstract_t\">35</a>]. Following completion of the initial phase of therapy for tuberculosis, in some circumstances, rifapentine can be used in the continuation phase of treatment in combination with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> in a once-weekly dosing regimen, thereby facilitating directly observed therapy. This regimen can be considered in HIV-uninfected patients without cavitary disease who were smear negative at two months [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/36\" class=\"abstract_t\">36</a>].</p><p>The United States Centers for Disease Control and Prevention (CDC) has recommended a three-month course of <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> and <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> administered once weekly for 12 weeks by directly observed therapy as an option for select high-risk adult persons with latent tuberculosis infection [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/37\" class=\"abstract_t\">37</a>]. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a> inhibits DNA-dependent RNA polymerase in susceptible strains of <em>M. tuberculosis</em>. Rifapentine is bactericidal against both intracellular and extracellular <em>M. tuberculosis</em> organisms.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strains of <em>M. tuberculosis</em> resistant to other rifamycins (including <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>) are likely to be resistant to <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a>, although drug susceptibility testing to rifapentine may be considered when rifampin resistance is observed and treatment options are limited.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a> absorption is increased in the presence of high-fat meals and divided doses [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/38\" class=\"abstract_t\">38</a>]. Rifapentine has high protein binding (97 percent) [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/30\" class=\"abstract_t\">30</a>]. The active metabolite is 25-desacetlyl rifapentine. Pharmacokinetic studies suggest that higher doses of the drug may be associated with higher concentrations of both free drug and metabolites [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/39\" class=\"abstract_t\">39</a>]. Most of the drug is eliminated in the feces (approximately 70 percent).</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dose of <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> for adults and children &gt;12 years of age is 10 <span class=\"nowrap\">mg/kg</span> (600 mg) by mouth in a single dose given once weekly during the continuation phase of treatment (in combination with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>) by directly observed therapy. </p><p>Limited data are available in children, but studies suggest the need for higher normalized weight-based dosing in order to achieve levels comparable with those in adults [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/40\" class=\"abstract_t\">40</a>]. For the treatment of latent tuberculosis (in combination with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>) in adults and children (&ge;2 years and &ge;10 kg), a single oral dose of <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> by mouth once weekly for 12 weeks (maximum of 900 <span class=\"nowrap\">mg/week)</span> by directly observed therapy is administered based on weight as follows: &ge;50 kg, 900 mg; 32.1 to 49.9 kg, 750 mg; 25.1 to 32 kg, 600 mg; 14.1 to 25 kg, 450 mg; and 10 to 14 kg, 300 mg.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Special populations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a> is not recommended for use in patients with HIV infection because relapse associated with acquired <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> monoresistance was observed in 6 percent of cases in this population during pilot studies [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/41\" class=\"abstract_t\">41</a>]. Rifapentine is not recommended for children &lt;12 years, pregnant or lactating women, or for individuals with culture-negative or extrapulmonary tuberculosis. </p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse effects of <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> are mild and usually confined to the gastrointestinal tract (eg, nausea and vomiting) and hepatotoxicity. Hyperuricemia and elevations in liver function tests have been reported [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/42\" class=\"abstract_t\">42</a>]. Rifapentine, like other rifamycins, may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and cerebrospinal fluid). Contact lenses and dentures can become permanently stained [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/36\" class=\"abstract_t\">36</a>].</p><p>When given once weekly with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> for treatment of latent tuberculosis infection, more serious reactions including hypotension and syncope have been reported, as well as a flu-like syndrome [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/43\" class=\"abstract_t\">43</a>]. Questioning about side effects with a previous dose may prevent a more serious event; prodromal symptoms require holding the next dose until a clinical evaluation is performed.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Drug interactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a>, like other rifamycins, is a strong inducer of the cytochrome P450 (CYP) system. Given limited data, rifapentine is not recommended for treatment of latent or active TB infection in patients receiving antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Information regarding the interactions between <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> (as a treatment for tuberculosis) and antiretrovirals is dynamic. The CDC maintains <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf&amp;token=kkT02sVuXs5PCPEO/DtNfsYTHWeQJLx6P+LbtzL+YXW0/foO4QI0FhWYCiQQxH8wd3+zyxhx6Ui8Ydd050FVIOhl5IuDIvRpccjiYOXT5Tg=&amp;TOPIC_ID=491\" target=\"_blank\" class=\"external\">guidelines</a> as to the management of such interactions [<a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Specific interactions of <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> with other medications may be determined by using the drug interaction tool (Lexi-Interact) included within UpToDate. This tool can be accessed via the Drug Interactions tab located in the top right corner of the screen or via the link within the Drug Interactions section of the individual drug monographs.</p><p class=\"headingAnchor\" id=\"H17082094\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rifamycins include <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>, and <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a>. Of these, rifampin is most commonly used as first-line therapy (in combination with other agents) for treatment of mycobacterial infections including tuberculosis and in select invasive staphylococcal infections. The rate of development of resistance to rifamycins is high; for this reason, these agents are not used as monotherapy except for rifampin prophylaxis against <em>Neisseria meningitidis</em> or <em>Haemophilus influenzae</em>. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H4\" class=\"local\">'Resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> undergoes rapid and complete absorption after oral administration. Absorption is improved when the drug is administered orally on an empty stomach. Rifampin undergoes wide distribution into most body tissues and fluids, including penetration into the cerebrospinal fluid. Intracellular concentrations (primarily in polymorphonuclear leukocytes) are up to five times higher than extracellular concentrations. (See <a href=\"#H6\" class=\"local\">'Pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> undergoes extensive hepatic metabolism to less active metabolites, with a half-life of three hours. Renal elimination of unchanged drug is minimal (&lt;30 percent); thus, no dose adjustments are required in patients with renal insufficiency. However, caution should be used when rifampin is administered to patients with significant hepatic disease, especially when used in combination with other hepatotoxins, such as <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>. (See <a href=\"#H6\" class=\"local\">'Pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-resistance of <em>Mycobacterium tuberculosis</em> isolates between rifamycins is not universal. Drug susceptibility testing to <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> or <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> might be considered in the setting of conventional <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> resistance and limited treatment options.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adverse effects associated with the administration of rifamycins include gastrointestinal, central nervous system, and dermatologic and hematologic effects. Rifamycins may produce an orange-red discoloration of body fluids (urine, tears, sputum, feces, and spinal fluid). Hepatitis is infrequently associated with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> but is more commonly observed in patients with predisposing factors, including administration of concomitant hepatotoxins such as <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>. Uveitis, a rare complication in patients receiving <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>, is most likely a consequence of elevated rifabutin serum concentrations due to interacting drugs. (See <a href=\"#H9\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients receiving <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> as part of combination antituberculous therapy should undergo baseline evaluations of hepatic enzymes (aspartate aminotransferase, bilirubin, alkaline phosphatase), platelet count, and serum creatinine prior to the initiation of therapy. (See <a href=\"#H10\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All patients must be educated about possible symptoms of hepatic toxicity. Patients should be questioned regarding these symptoms at visits and should report any signs or symptoms that occur between visits. All patients should be fully evaluated clinically, including serum testing for hepatic injury. (See <a href=\"#H10\" class=\"local\">'Monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug interactions result from the ability of rifamycins to induce the cytochrome P450 isoenzyme CYP3A4 (and to lesser extent CYP2C8 and CYP2C9) and uridine diphosphate gluconyltransferase (UGT) 1A1 enzymes, potentially decreasing serum concentrations of coadministered drugs. In addition, serum concentrations of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> (a substrate of CYP-3A4) may be altered by inducers or inhibitors of this enzyme. (See <a href=\"#H1657985304\" class=\"local\">'Drug interactions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">Rifabutin</a> is most commonly used in the treatment of mycobacterial infections in patients receiving concomitant medications exhibiting significant interactions with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> (such as select antiretroviral therapies).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">Rifapentine</a> has a longer half-life than <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>. In some circumstances, rifapentine can be used in the continuation phase of treatment (in combination with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>) in a once-weekly dosing regimen, thereby facilitating directly observed therapy. However, rifapentine should not be used for patients with HIV infection, children &lt;12 years, pregnant or lactating women, or for individuals with culture-negative or extrapulmonary tuberculosis. Rifapentine also may be used for treatment of latent tuberculosis infection in a 12-week once-weekly regimen with isoniazid by directly observed therapy in select high-risk groups. (See <a href=\"#H12\" class=\"local\">'Rifapentine'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Centers for Disease Control. Core Curriculum on Tuberculosis-1994.</li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/2\" class=\"nounderline abstract_t\">Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23:14.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/3\" class=\"nounderline abstract_t\">Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001; 104:901.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/4\" class=\"nounderline abstract_t\">Yuen LK, Leslie D, Coloe PJ. Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37:3844.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/5\" class=\"nounderline abstract_t\">Wichelhaus TA, Sch&auml;fer V, Brade V, B&ouml;ddinghaus B. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:2813.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/6\" class=\"nounderline abstract_t\">Padayachee T, Klugman KP. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:2361.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/7\" class=\"nounderline abstract_t\">Drancourt M, Raoult D. Characterization of mutations in the rpoB gene in naturally rifampin-resistant Rickettsia species. Antimicrob Agents Chemother 1999; 43:2400.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/8\" class=\"nounderline abstract_t\">Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42:1853.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/9\" class=\"nounderline abstract_t\">Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10:662.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/10\" class=\"nounderline abstract_t\">Sirgel FA, Warren RM, B&ouml;ttger EC, et al. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013; 8:e59414.</a></li><li class=\"breakAll\">Zhang Y, Vilcheze C, Jacobs WR. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: Tuberculosis and the tubercle bacillus, ASM Press, Washington, DC 2005. p.125.</li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/12\" class=\"nounderline abstract_t\">Farr B, Mandell GL. Rifampin. Med Clin North Am 1982; 66:157.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/13\" class=\"nounderline abstract_t\">Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother 2016; 60:2171.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/14\" class=\"nounderline abstract_t\">Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115:12.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/15\" class=\"nounderline abstract_t\">Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16:1546.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/16\" class=\"nounderline abstract_t\">Jeremiah K, Denti P, Chigutsa E, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. Antimicrob Agents Chemother 2014; 58:3468.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/17\" class=\"nounderline abstract_t\">Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis 1972; 125:486.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/18\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/19\" class=\"nounderline abstract_t\">Mart&iacute;nez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999; 78:361.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/20\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/21\" class=\"nounderline abstract_t\">Vesely JJ, Pien FD, Pien BC. Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 1998; 18:345.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/22\" class=\"nounderline abstract_t\">Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992; 22:47.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/23\" class=\"nounderline abstract_t\">Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335:126.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/24\" class=\"nounderline abstract_t\">Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 2013; 29:1.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/25\" class=\"nounderline abstract_t\">Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004; 43:725.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/26\" class=\"nounderline abstract_t\">Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. J Pharm Biomed Anal 1997; 15:1571.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/27\" class=\"nounderline abstract_t\">Kyrklund C, Backman JT, Kivist&ouml; KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000; 68:592.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/28\" class=\"nounderline abstract_t\">Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003; 42:819.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm (Accessed on December 08, 2014).</li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/30\" class=\"nounderline abstract_t\">Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40:327.</a></li><li class=\"breakAll\">AIDS info. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Accessed on December 08, 2014).</li><li class=\"breakAll\">Mycobutin [package insert]. New York, NY: Pharmacia &amp; Upjohn Company; 2007.</li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/33\" class=\"nounderline abstract_t\">Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995; 29:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/34\" class=\"nounderline abstract_t\">Kakuda TN, Sch&ouml;ller-Gy&uuml;re M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011; 50:25.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/35\" class=\"nounderline abstract_t\">Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/36\" class=\"nounderline abstract_t\">Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006; 43:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/37\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/38\" class=\"nounderline abstract_t\">Dooley KE, Savic RM, Park JG, et al. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother 2015; 59:3399.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/39\" class=\"nounderline abstract_t\">CONWAY N, BIRT BD. STREPTOMYCIN IN PREGNANCY: EFFECT ON THE FOETAL EAR. Br Med J 1965; 2:260.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/40\" class=\"nounderline abstract_t\">Blake MJ, Abdel-Rahman SM, Jacobs RF, et al. Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006; 25:405.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/41\" class=\"nounderline abstract_t\">ROBINSON GC, CAMBON KG. HEARING LOSS IN INFANTS OF TUBERCULOUS MOTHERS TREATED WITH STREPTOMYCIN DURING PREGNANCY. N Engl J Med 1964; 271:949.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/42\" class=\"nounderline abstract_t\">Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56:607.</a></li><li><a href=\"https://www.uptodate.com/contents/rifamycins-rifampin-rifabutin-rifapentine/abstract/43\" class=\"nounderline abstract_t\">Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis 2015; 61:527.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 491 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17082094\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">RIFAMPIN</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanism of action</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Resistance</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Spectrum of in vitro activity</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Pharmacokinetics</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Dosing and administration</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Special populations</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Adverse effects</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Monitoring</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Drug interactions</a></li></ul></li><li><a href=\"#H1657985256\" id=\"outline-link-H1657985256\">RIFABUTIN</a><ul><li><a href=\"#H1657985262\" id=\"outline-link-H1657985262\">Mechanism of action</a></li><li><a href=\"#H1657985268\" id=\"outline-link-H1657985268\">Resistance</a></li><li><a href=\"#H1657985274\" id=\"outline-link-H1657985274\">Pharmacokinetics</a></li><li><a href=\"#H1657985280\" id=\"outline-link-H1657985280\">Dosing</a></li><li><a href=\"#H1657985286\" id=\"outline-link-H1657985286\">Special populations</a></li><li><a href=\"#H1657985292\" id=\"outline-link-H1657985292\">Adverse effects</a></li><li><a href=\"#H1657985298\" id=\"outline-link-H1657985298\">Monitoring</a></li><li><a href=\"#H1657985304\" id=\"outline-link-H1657985304\">Drug interactions</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">RIFAPENTINE</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Mechanism of action</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Resistance</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Pharmacokinetics</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Dosing</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Special populations</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Adverse effects</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Monitoring</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Drug interactions</a></li></ul></li><li><a href=\"#H17082094\" id=\"outline-link-H17082094\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antimicrobial-therapy-of-prosthetic-valve-endocarditis\" class=\"medical medical_review\">Antimicrobial therapy of prosthetic valve endocarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">Antituberculous drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">Isoniazid hepatotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-mycobacterium-avium-complex-lung-infection-in-adults\" class=\"medical medical_review\">Treatment of Mycobacterium avium complex lung infection in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li></ul></div></div>","javascript":null}